HS-10296 hydrochloride is primarily utilized in the field of medical research and drug development. It is investigated for its potential as a therapeutic agent, particularly in the treatment of non-small cell lung cancer (NSCLC) with EGFR (Epidermal Growth Factor Receptor) mutations. The compound acts as a selective inhibitor of mutated EGFR protein kinases, which play a crucial role in cell signaling and proliferation. By targeting these kinases, it helps control the growth of cancer cells, induce apoptosis, and inhibit disease metastasis. Researchers are exploring its efficacy in combination with other anticancer drugs to enhance treatment outcomes. Additionally, it is studied for applications in other EGFR mutation-related cancers and diseases with dysregulated kinase activity. Preclinical studies provide insights into its mechanism of action and therapeutic potential.